Disclaimer

The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Day

June 6, 2024
PRESS RELEASE REGULATED INFORMATION 6 JUNE, 2024, 07.00 CEST Sequana Medical announces data on alfapump® safety and quality of life to be presented at EASL Congress 2024 “alfapump implantation significantly improved quality of life and showed similar safety outcomes compared to a contemporaneously enrolled refractory ascites cohort”;oral poster presentation by Dr. Bajaj Matched cohort analysis...
Read More

PRESS RELEASES

SUBSCRIBE TO OUR PRESS RELEASES